Finance

Lists
Q2 2026 earnings • released • EPS beat +4.20% • Revenue miss -1.48%
See results
EXEL:NASDAQ
Exelixis Inc
$52.20
-7.94%
(-4.50) 1D
$52.20
0.00% (0.00)
After hours
Closed: Aug 6, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EXEL...
Open
$52.92
High
$55.44
Low
$51.76
Mkt. cap
13.12B
Avg. vol.
0.00
Volume
15.00
P/E ratio
17.30
52-wk high
$57.57
52-wk low
$33.76
EPS
$3.02
Beta
0.44
Shares outstanding
251.36M
No. of employees
1K
Open
$52.92
High
$55.44
Low
$51.76
Mkt. cap
13.12B
Avg. vol.
0.00
Volume
15.00
P/E ratio
17.30
52-wk high
$57.57
52-wk low
$33.76
EPS
$3.02
Beta
0.44
Shares outstanding
251.36M
No. of employees
1K
News stories
From sources across the web
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com
Analyst ratings
Based on 14 analysts giving stock ratings to EXEL in the past 3 months
Hold
Buy
4
Hold
9
Sell
1
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for EXEL in the last 3 months.
Highest
Current $52.20
$64.00 (+22.61%)
Average
$51.75 (-0.86%)
Lowest
$41.00 (-21.46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
08/06/2026
Andrew Berens
Leerink Partners
Hold
Downgraded
$52.00
-0.4%
08/06/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$64.00
+22.6%
08/05/2026
Stephen Willey
Stifel Nicolaus
Hold
Maintained
$51.00
-2.3%
08/06/2026
Gregory Renza
Truist Financial
Hold
Maintained
$52.00
-0.4%
08/06/2026
Derek Archila
Wells Fargo
Hold
Reiterated
$50.00
-4.2%
08/06/2026
Sean Laaman
Morgan Stanley
Hold
Maintained
$53.00
+1.5%
08/06/2026
Leonid Timashev
RBC Capital
Hold
Maintained
$46.00
-11.9%
08/06/2026
Yaron Werber
TD Cowen
Buy
Maintained
$55.00
+5.4%
08/05/2026
Jason Gerberry
Bank of America Securities
Sell
Reiterated
$41.00
-21.5%
08/05/2026
Etzer Darout
Barclays
Hold
Maintained
$49.00
-6.1%
08/06/2026
Andy Hsieh
William Blair
Buy
Maintained
-
-
08/06/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Maintained
$49.00
-6.1%
07/13/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$49.00
-6.1%
07/13/2026
Ashwani Verma
UBS
Hold
Reiterated
$52.00
-0.4%
07/02/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$56.00
+7.3%
07/02/2026
Unknown Analyst
Jefferies
Buy
Maintained
$47.00
-10%
03/25/2026
Jay Olson
Oppenheimer
Hold
Maintained
$36.00
-31%
03/03/2026
Unknown Analyst
Stephens
Buy
Maintained
$60.00
+14.9%
02/11/2026
Michael Schmidt
Guggenheim
Hold
Maintained
-
-
02/10/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.91 / $0.87
+4.20%beat
Revenue / Est. (USD)
628.69M / 638.16M
-1.48%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
568.26M
597.76M
598.66M
610.81M
Cost of goods sold
19.47M
18.57M
26.48M
19.95M
Cost of revenue
19.47M
18.57M
26.48M
19.95M
Research and development expenses
200.36M
199.16M
213.25M
199.92M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
134.86M
123.66M
123.02M
139.60M
Operating expense
335.22M
322.82M
336.27M
339.52M
Total operating expenses
354.68M
341.40M
362.75M
359.47M
Operating income
213.58M
256.36M
235.91M
251.34M
Other non operating income
50.00K
-49.00K
46.00K
219.00K
EBT including unusual items
230.42M
252.41M
252.69M
267.69M
EBT excluding unusual items
230.42M
272.23M
253.38M
267.69M
Income tax expense
45.57M
58.84M
8.16M
57.22M
Effective tax rate
19.78%
23.31%
3.23%
21.38%
Other operating expenses
-
-
-
-
Net income
184.85M
193.58M
244.53M
210.47M
Net profit margin
32.53%
32.38%
40.85%
34.46%
Earnings per share
0.75
0.78
0.94
0.87
Interest and investment income
16.79M
15.92M
17.43M
16.13M
Interest expense
-
-
-
-
Net interest expenses
16.79M
15.92M
17.43M
16.13M
Depreciation and amortization charges
-
-
-
-
EBITDA
220.92M
263.78M
242.86M
258.29M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps